Methodology that accurately predicts if cancer-derived neoantigens are processed and bind to human leukocyte antigen molecules (HLA) has been a challenge. “Mutation-associated neoantigen-selected reaction monitoring” (MANA-SRM) is a novel technique that directly detects and quantifies HLA-binding MANA.